Montelukast Tarbis Farma

Montelukast, the active ingredient in Montelukast Tarbis Farma, is a leukotriene receptor antagonist presented as an oral tablet for oral use. It is used to manage asthma, exercise‑induced bronchoconstriction and allergic rhinitis in adults and children as directed by a healthcare professional.

GNH USA supplies Montelukast Tarbis Farma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Montelukast acts on the leukotriene pathway to reduce airway inflammation and bronchoconstriction. - Asthma prophylaxis: helps prevent chronic asthma symptoms and reduces the frequency of attacks. - Exercise‑induced bronchoconstriction: lessens airway narrowing that occurs during or after physical activity. - Allergic rhinitis: alleviates nasal congestion, sneezing and itching caused by seasonal or perennial allergies.

Montelukast is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Headache: mild to moderate pain in the head. - Upper respiratory tract infection: symptoms such as sore throat or nasal congestion. - Abdominal pain: discomfort or cramps in the stomach area. - Cough: persistent dry cough. - Diarrhoea: loose stools. - Rash: mild skin irritation or redness.

Serious or Rare Side Effects: - Mood changes: depression, anxiety, or suicidal thoughts. - Hepatic dysfunction: elevated liver enzymes or hepatitis. - Allergic reactions: angioedema, urticaria, or anaphylaxis. - Stevens‑Johnson syndrome: severe skin blistering. - Blood dyscrasias: neutropenia or eosinophilia. - Cardiovascular events: rare cases of chest pain or palpitations.

Before prescribing Montelukast, clinicians should consider several safety aspects. - Pregnancy: evaluate risk‑benefit as safety data are limited. - Breastfeeding: assess potential exposure to the infant. - Hepatic impairment: monitor liver function in patients with existing liver disease. - Psychiatric history: watch for mood alterations, especially in adolescents. - Concomitant asthma therapy: ensure patients continue rescue inhalers for acute symptoms. - Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Montelukast may interact with other medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Phenobarbital: may decrease montelukast plasma concentrations. - Rifampin: induces metabolism leading to lower drug exposure.

Moderate Interactions (Monitor Closely): - Antidepressants (e.g., fluoxetine): potential for additive neuropsychiatric effects. - Antihistamines: may increase sedation when combined with sedating antihistamines. - CYP2C9 inhibitors (e.g., fluconazole): could modestly raise montelukast levels. - Warfarin: monitor INR as occasional reports suggest altered anticoagulation. - Vaccines: observe for atypical immune responses when administered concurrently.